Eli Lilly to buy Versanis for up to $1.93bn in obesity drugs push

Eli Lilly and Co has announced that it will buy privately held Versanis for potentially up to $1.93bn to strengthen its position in the fast-growing market for weight-loss treatments.

The deal would give it access to Versanis’s drug, bimagrumab, which acts directly on fat cells without reducing appetite and without prompting lean mass loss. These drugs belong to a class of treatments known as incretins that are designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow stomach emptying and decrease appetite.

To find out more, CLICK HERE.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags